Zydus Cadila on Thursday said it is seeking permission from Drugs Controller General of India to initiate human clinical trials for monoclonal antibodies cocktail for treatment of COVID-19. “Zydus is currently seeking permission to initiate phase 1/3 human clinical trials from the DCGI… ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies can emerge as one of the main treatments for …
Drug firm Zydus Cadila on Friday announced that it has received approvals to start Phase III clinical trials of its Covid-19 vaccine candidate ZyCoV-D in India. Last month, Cadila Healthcare Ltd said that it aims to supply between 100 million to 150 million doses of its COVID-19 vaccine candidate ZyCoV-D this calendar year. Meanwhile, India started its mass vaccination against …
Cadila Healthcare Ltd. aims to supply between 100 million to 150 million doses of its COVID-19 vaccine candidate ZyCoV-D this calendar year. "Based on the recommendations of the Subject Expert Committee, which reviewed the interim data, the DCGI has accorded permission for conducting Phase-III clinical trial in 26,000 Indian participants," the Ministry said. Over 1,000 participants took part in the …
)
